Tumor Necrosis Factor Blocker [EPC]

728863 reported adverse events

Drugs of this class: ETANERCEPT GOLIMUMAB INFLIXIMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	79444
1	INJECTION SITE PAIN	56328
2	ARTHRALGIA	43991
3	INJECTION SITE ERYTHEMA	41074
4	RHEUMATOID ARTHRITIS	39039
5	PAIN	38101
6	OFF LABEL USE	29427
7	FATIGUE	27838
8	PSORIASIS	26261
9	PAIN IN EXTREMITY	25101

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	INJECTION SITE RECALL REACTION	481	0.9816
1	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	280	0.9756
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	735	0.8429
3	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1314	0.8423
4	RHEUMATOID FACTOR POSITIVE	1213	0.8092
5	C-REACTIVE PROTEIN ABNORMAL	2005	0.7875
6	INJECTION SITE MACULE	467	0.7343
7	SYNOVITIS	5148	0.6508
8	INJECTION SITE WARMTH	10374	0.6427
9	PEMPHIGUS	1676	0.6007

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]